

ReSIGHT

Leber's Hereditary Optic Neuropathy



A randomized, double-masked, vehicle-controlled study to evaluate the safety, tolerability and efficacy of 52 weeks' treatment with twice-daily topical eye drop formulation of elamipretide to treat patients with Leber's Hereditary Optic Neuropathy (LHON), the most common mitochondrial optic neuropathy.

Principal Investigator: Alfredo Sadun, MD



~10,000

people in the United States have LHON

>20

mitochondrial optic neuropathies

SUBJECTS WITH LOSS OF VISION
IN BOTH EYES FROM LHON



TRIAL BEGAN
Q2 2016

TRIAL SITES

1 trial center

Los Angeles, California



ENDPOINTS

PRIMARY

Safety and tolerability

SECONDARY

Change in visual function, field and electrical response of retinal ganglion cells
Retinal biomarkers measured by spectral domain optical coherence tomography